Aclaris Therapeutics (ACRS) Cash & Current Investments (2014 - 2026)

Aclaris Therapeutics' Cash & Current Investments history runs 13 years deep, the most recent figure standing at $105.4 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments changed 0.1% year-over-year to $105.4 million in Q1 2026; TTM through Mar 2026 was $105.4 million, a 0.1% change from a year earlier, with the FY2025 full-year figure at $90.8 million, down 20.11% from the prior year.
• Cash & Current Investments grew to $105.4 million in Q1 2026 per ACRS's latest filing, from $90.8 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $248.6 million in Q2 2022 and bottomed at $90.8 million in Q4 2025.
• The 5-year median for Cash & Current Investments is $119.1 million (2023), against an average of $140.3 million.
• Across the five-year window, Cash & Current Investments jumped 40.01% in 2022 and slumped 58.46% in 2023, its largest moves.
• Year by year, Cash & Current Investments stood at $217.6 million in 2022, then slumped by 45.26% to $119.1 million in 2023, then slipped by 4.63% to $113.6 million in 2024, then retreated by 20.11% to $90.8 million in 2025, then rose by 16.16% to $105.4 million in 2026.
• Per Business Quant, the three latest ACRS Cash & Current Investments figures stand at $105.4 million (Q1 2026), $90.8 million (Q4 2025), and $95.9 million (Q3 2025).